eoxycorticosterone acetate (DOCA) with 1% salt in drinking water (DOCA-salt) results in salt and water retention, plasma volume expansion, and hypertension that are associated with low levels of angiotensin II (Ang II). 1 However, levels of arginine vasopressin (AVP), catecholamines, and endothelin-1 (ET-1) are increased in this model and contribute to hypertension.
D
eoxycorticosterone acetate (DOCA) with 1% salt in drinking water (DOCA-salt) results in salt and water retention, plasma volume expansion, and hypertension that are associated with low levels of angiotensin II (Ang II). 1 However, levels of arginine vasopressin (AVP), catecholamines, and endothelin-1 (ET-1) are increased in this model and contribute to hypertension. [2] [3] [4] These agents also activate phospholipase A 2 and release arachidonic acid (AA) from tissue phospholipids. [5] [6] [7] Metabolites of AA generated via lipoxygenase or cytochrome P450 (CYP) 4A ω-hydroxylase have been implicated in spontaneous hypertensive rats, as well as Ang II and DOCA-salt models of hypertension. [8] [9] [10] [11] [12] Metabolism of AA also results in generation of reactive oxygen species (ROS) that cause endothelial dysfunction and contribute to the development of various models of hypertension, including DOCA-salt-induced hypertension.
nonselective effect of 2,3′,4,5′-tetramethoxystilbene in that study. Moreover, the role of CYP1B1 in cardiac dysfunction and renal damage and inflammation was not examined. Therefore, to test the hypothesis that CYP1B1 contributes to cardiovascular dysfunction, renal damage, and inflammation, via increased production of ROS, and activity of neurohumoral factors and various signaling molecules in DOCA-saltinduced hypertension, this study was performed in wildtype (Cyp1b1
+/+
) and Cyp1b1 gene-disrupted (Cyp1b1 −/− ) mice. The results of this study provide, for the first time, strong evidence that, in DOCA-salt hypertension in mice, Cyp1b1 plays a major role in cardiovascular dysfunction and renal damage and inflammation, consequent to generation of ROS and activation of ≥1 signaling molecules, including extracellular signal-regulated kinase (ERK)1/2, p38 mitogenactivated protein kinase (MAPK), and cellular-Src (c-Src), independent of eicosanoids.
Methods
For a detailed description of Methods, please see the online-only Data Supplement.
Results

Cyp1b1 Gene Disruption Minimizes DOCASalt-Induced Hypertension in Mice
Systolic blood pressure (SBP) in Cyp1b1 +/+ and Cyp1b1 −/− mice was measured by tail-cuff method. Although this method has some limitations, 25 DOCA-salt treatment caused a substantial increase in SBP in both Cyp1b1 +/+ and Cyp1b1 −/− mice over a period of 28 days, and there was a consistent and highly significant difference in the SBP between these 2 groups without any change in the basal pressure in the corresponding sham controls (Figure 1) . Therefore, the differences observed in SBP measured by tail cuff in Cyp1b1 +/+ and Cyp1b1 −/− mice treated with DOCA-salt are most likely accurate.
DOCA-Salt-Induced Hypertension Is Associated With Increased CYP1B1 Activity but Not Expression in Mice
In hearts and kidneys of DOCA-salt-treated Cyp1b1 +/+ mice, CYP1B1 activity was increased compared with sham-operated Cyp1b1 +/+ mice ( Figure S1A and S1C, respectively, in the online-only Data Supplement). CYP1B1 protein expression was unchanged in hearts and kidneys of sham-operated and DOCA-salt-treated Cyp1b1 +/+ mice ( Figure S1B and S1D, respectively). Cyp1b1 gene disruption and DOCA-salt treatment had no effect on protein expression of other AA metabolizing enzymes in cardiac or renal homogenates ( Figure S2A and S2B, respectively).
Cyp1b1 Gene Disruption Minimizes Cardiac Hypertrophy and Dysfunction Associated With DOCA-Salt-Induced Hypertension in Mice
DOCA-salt treatment increased heart weight:body weight ratio, an indicator of cardiac hypertrophy in Cyp1b1 +/+ mice; this increase was reduced in Cyp1b1 −/− mice (Table S1 ). Echocardiography revealed impaired systolic function, as indicated by decreased fractional shortening and ejection fraction in DOCA-salt-treated Cyp1b1 +/+ mice (Table) . Impaired diastolic function, as indicated by a decrease in the ratio of tissue mitral annulus early longitudinal:atria velocity, was also observed in DOCA-salt-treated Cyp1b1 +/+ but not in Cyp1b1 −/− mice (Table) . DOCA-salt treatment also resulted in an increase in the thickness of the interventricular septum, the posterior and anterior wall of the left ventricle during diastole, but not systole, and increased the left ventricle internal diameter of Cyp1b1 +/+ mice; these changes were decreased or absent in the hearts of Cyp1b1 −/− mice (Table S2) . DOCA-salt treatment also caused an increase in both end-diastolic volume and end-systolic volume in Cyp1b1 +/+ but not in Cyp1b1 −/− mice; however, no difference in stroke volume was found in either sham-operated or DOCA-salt-treated Cyp1b1 +/+ and Cyp1b1 −/− mice (Table S2) . The response to phenylephrine (PE) and ET-1 of the renal artery from DOCA-salt-treated Cyp1b1 +/+ mice was increased compared with sham-operated Cyp1b1 +/+ mice ( Figure S3A and S3B, respectively). In DOCA-salt-treated Cyp1b1 −/− mice, no increase in response to PE was observed compared with shamoperated Cyp1b1 −/− mice ( Figure S3A) ; however, the response of the renal artery to ET-1 was increased from DOCA-salt-treated Cyp1b1 −/− mice compared with sham-operated Cyp1b1 −/− mice; this increase was less than that seen in Cyp1b1 +/+ mice ( Figure  S3B ). The concentration of ET-1 used produced a somewhat greater magnitude of contractile response than that produced by PE, but the decreases in vascular reactivity to PE and ET-1 produced by Cyp1b1 gene disruption were not significantly different (35 
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Cyp1b1 +/+ mice correlated with an increase in media:lumen ratio, an indicator of vascular smooth muscle hypertrophy (Table  S3 ). In the renal artery of DOCA-salt-treated Cyp1b1 −/− mice, the media:lumen ratio was also increased, but this increase was less than that observed in Cyp1b1 +/+ mice (Table S3) . DOCA-salt treatment was also associated with endothelial dysfunction of the renal artery from Cyp1b1 +/+ mice, as demonstrated by a decreased relaxation response to increasing concentrations of acetylcholine compared with sham-operated Cyp1b1 +/+ mice ( Figure S3C ). The renal artery from DOCA-salt-treated Cyp1b1 −/− mice also displayed endothelial dysfunction, but this was improved compared with the endothelial dysfunction observed in Cyp1b1 +/+ mice ( Figure S3C ). Endothelium-independent relaxations to sodium nitroprusside were not different in renal arteries from mice in any of the treatment groups ( Figure S3D ).
Basal renal blood flow was not different between Cyp1b1
and Cyp1b1 −/− mice (Table S4) Figure S4 ).
Cyp1b1 Gene Disruption Does Not Protect Against Renal Hypertrophy but Decreases Proteinuria Associated With DOCA-Salt-Induced Hypertension in Mice
In both Cyp1b1 +/+ and Cyp1b1 −/− mice, DOCA-salt treatment resulted in hypertrophy of the remaining kidney, as indicated by increased kidney weight:body weight ratio (Table S5) . DOCAsalt treatment was also associated with increased proteinuria in Cyp1b1 +/+ and Cyp1b1 −/− mice; however, the increase in proteinuria was reduced in Cyp1b1 −/− mice (Table S5 ). (Table S6) . DOCAsalt treatment increased plasma levels of catecholamines, ET-1, and AVP in Cyp1b1 +/+ mice; these increases were reduced or absent in DOCA-salt-treated Cyp1b1 −/− mice (Table S6) . Figure S5A and S5D, respectively). The increase in superoxide production in DOCA-salt-treated Cyp1b1 +/+ mice was associated with an increase in cardiac and renal nicotinamide adenine dinucleotide phosphate (NADPH) oxidase activity ( Figure S5B and S5E, respectively) and protein expression of NOX1 ( Figure S5C and S5F, respectively); these increases were also attenuated in hearts and kidneys of Cyp1b1 −/− mice treated with DOCA-salt ( Figure S5B , S5C, S5E, and S5F, respectively). 
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Discussion
This study demonstrates for the first time that CYP1B1 plays a crucial role in the cardiovascular dysfunction, and renal damage and inflammation associated with DOCA-salt-induced hypertension, as a result of ROS production via increased activity of NADPH oxidase, and activation of ERK1/2, p38 MAPK, and c-Src in mice. Administration of DOCA-salt in Cyp1b1 +/+ mice increased SBP and CYP1B1 activity in the heart and kidney without altering expression levels or shifting the CYP1B1 protein bands on Western blots. The mechanism by which DOCA-salt treatment increases CYP1B1 activity, which could be attributed to a biochemical modification of this enzyme or involvement of some other endogenous factor(s), including increased P450 reductase, NADPH levels, or both, remains to be determined.
DOCA-salt treatment caused cardiac hypertrophy and dysfunction in Cyp1b1 +/+ mice as indicated by the following: (1) increased heart weight:body weight ratio; (2) increased thickness of the interventricular septum, and posterior and anterior walls of the left ventricle during diastole, and increased left ventricle internal diameter; (3) increased end-diastolic and end-systolic volume; (4) impaired diastolic function as indicated by decreased tissue mitral annulus early longitudinal:atria velocity ratio; and (5) impaired systolic function as indicated by decreased fractional shortening and ejection fraction. Our finding that Cyp1b1 gene disruption in mice prevented or minimized these cardiac changes produced by DOCA-salt suggests that CYP1B1 is required for the cardiac dysfunction associated with DOCA-salt-induced hypertension. Although an increase in BP caused by DOCA-salt was reduced, it was not prevented in Cyp1b1 −/− mice, suggesting that the cardiac dysfunction in these mice is, in part, independent of BP as reported by other investigators. 26, 27 Our finding that a component of DOCA-salt-induced hypertension is resistant to Cyp1b1 gene disruption in mice suggests that factors other than CYP1B1 also contribute to the development of hypertension in this model. Recently, it has been shown that mice lacking leukocyte-type 12/15-lipoxygenase are resistant to DOCA-salt-and N G -nitro-l-arginine-methyl esterinduced hypertension and that macrophage and not vascular leukocyte-type 12/15-lipoxygenase is required for N G -nitro-larginine-methyl ester-induced hypertension. 28 Whether these mice are also resistant to the cardiovascular dysfunction and infiltration of macrophages and T cells associated with DOCAsalt hypertension is not known. In our study, Cyp1b1 gene disruption did not alter the expression of other CYP isoforms, COX1, COX2, or 12/15-lipoxygenase in the hearts or kidneys of DOCA-salt-treated mice.
DOCA-salt-induced hypertension is also associated with increased vascular reactivity and endothelial dysfunction. 29, 30 Our findings that increased response of the renal artery to PE and ET-1; hypertrophy, as indicated by increased media:lumen ratio; endothelial dysfunction, as indicated by the loss of acetylcholine-induced but not sodium nitroprusside-induced relaxation; and increased renal vascular resistance in DOCAsalt-treated Cyp1b1 +/+ mice were minimized or abolished in Cyp1b1 −/− mice also support the role of CYP1B1 in these pathophysiological changes that may also contribute to DOCA-salt-induced hypertension.
DOCA-salt treatment in Cyp1b1 +/+ mice also caused the following: (1) hypertrophy of the remaining kidney, as observed by increased kidney weight:body weight ratio; (2) marked proteinuria; (3) interstitial fibrosis, as indicated by increased accumulation of interstitial α-smooth muscle actin; (4) proteinaceous cast formation; (5) tubular dilation; and (6) inflammation, as shown by increased infiltration of F4/80 + macrophages and CD-3 + lymphocytes in the glomerulus. The demonstration that these pathophysiological changes, except hypertrophy of the kidney, were minimized in Cyp1b1 −/− mice treated with DOCA-salt suggests a crucial role of CYP1B1 in renal dysfunction, end-organ damage, and inflammation associated with DOCA-salt hypertension. Moreover, it appears that the renal hypertrophy caused by DOCA-salt treatment is not the result of these CYP1B1-dependent pathophysiological changes.
The mechanism by which CYP1B1 promotes DOCAsalt-induced hypertension, cardiovascular hypertrophy and dysfunction, endothelial and renal dysfunction, and end-organ damage and inflammation could be attributed to increased release of AA consequent to activation of phospholipase A 2 by catecholamines, AVP, and ET-1.
5-7 AA can be metabolized by CYP1B1 in vitro into various eicosanoids, including 12-and 20-HETE and epoxy eicosatrienoic acids, 18 which contribute to pro-and anti-hypertensive mechanisms, respectively. [31] [32] [33] Moreover, metabolism of AA by CYP1B1 in vascular smooth muscle cells results in generation of ROS 19 that have been implicated in various models of experimental hypertension, including DOCA-salt hypertension and associated pathophysiological changes. [13] [14] [15] [16] [17] In a previous study, we found that infusion of Ang II for 13 and 28 days increased the levels of 12-and 20-HETE in the kidneys of Cyp1b1 +/+ but not Cyp1b1 −/− mice. 22 In DOCAsalt-induced hypertension, urinary excretion of 20-HETE is also increased; this increase is mediated by ET-1, and both 20-HETE and ET-1 contribute to hypertension. 34 In contrast, other studies have shown that renal tissue levels of 20-HETE are reduced, and this is associated with decreased expression of CYP4A in DOCA-salt hypertension. 35, 36 20-HETE exerts prohypertensive effects by causing renal vascular constriction but exerts an antihypertensive effect by increasing Na + and water excretion. 32 In the present study, DOCA-salt treatment did not alter levels of any HETEs and epoxyeicosatrienoic acids measured in the hearts or kidneys of Cyp1b1 +/+ and Cyp1b1 −/− mice. Moreover, Cyp1b1 gene disruption, DOCA-salt treatment, or both did not alter cardiac or renal expression of other CYP isoforms or AA metabolizing enzymes. Currently, we have no explanation for these discrepancies. However, in view of the unchanged levels of eicosanoids determined in this study, it is unlikely that they contribute to the increased levels of catecholamines, AVP, or ET-1 and the end-organ damage produced by DOCA-salt.
Previously, we have reported that AA-and Ang II-induced activation of NADPH oxidase and ROS production is dependent on CYP1B1 activity. 19 Therefore, it is possible that ROS generated via CYP1B1 could mediate the cardiovascular and renal dysfunction, end-organ damage, and development of hypertension caused by DOCA-salt. 37 Supporting this view was our demonstration that ROS production in the heart, renal artery, and kidney, and NADPH oxidase activity and expression of NOX1 measured in the heart and kidney, were increased in DOCA-salt-treated Cyp1b1 +/+ mice but were minimized in these tissues of Cyp1b1 −/− mice. Whether other NOX isoforms contribute to the increase in NADPH oxidase activity that is dependent on CYP1B1 remains to be determined. Our demonstration that the levels of catecholamines, AVP, and ET-1 that were increased in DOCA-salt-treated Cyp1b1 +/+ mice were reduced in Cyp1b1 −/− mice raises the possibility that CYP1B1 via generation of ROS in the brain might also amplify sympathetic activity and release of catecholamines, AVP, and ET-1 that, in turn, further stimulate ROS production in cardiovascular and renal tissues. [38] [39] [40] Cyp1b1 mRNA is present in different brain regions, 41 and ROS are known to stimulate both central and peripheral sympathetic activity and ET-1 production. [42] [43] [44] [45] Ang II-, DOCA-salt-, or aldosterone-induced hypertension and endothelial dysfunction, increased oxidative stress, and cardiovascular and renal damage have been reported to be associated with increased activation or infiltration of immune cells or both. [46] [47] [48] [49] These effects are diminished in severe combined immunodeficiency, 46 by depletion of macrophages, 47, 48 or in Rag-1 −/− mice 49 or by adaptive transfer of T-lymphocyte regulatory cells (CD4 + and CD25 + cells). 50, 51 The presence of CYP1B1 in macrophages and T lymphocytes, 52 ,53 together with our demonstration that infiltration of macrophages and T lymphocytes in the kidney of DOCA-salt-treated Cyp1b1 +/+ mice were reduced in Cyp1b1 −/− mice, raises the possibility that lipid peroxides, ROS, or both generated from AA via CYP1B1 in macrophages and T lymphocytes might be involved in their activation and infiltration in renal tissues.
ROS generated via CYP1B1 could cause cardiovascular and renal dysfunction, end-organ damage, and inflammation in DOCA-salt-treated Cyp1b1 +/+ mice by activating various signaling molecules, including ERK1/2, p38 MAPK, and c-Src. [54] [55] [56] Evidence supporting this notion was our observation that DOCA-salt treatment increased the activity of these signaling molecules in hearts and kidneys of Cyp1b1 +/+ mice but not in these tissues of Cyp1b1 −/− mice. Dyshomeostasis of divalent cations has also been demonstrated to result in oxidative stress and cardiac damage caused by aldosterone and salt. 57 Whether CYP1B1 is involved in ROS production caused by divalent cation dyshomeostasis remains to be determined.
In conclusion, the present study shows that CYP1B1 plays a significant role in the cardiovascular and renal dysfunction, endorgan damage and inflammation, and hypertension caused by DOCA-salt, via generation of ROS by stimulation of NADPH oxidase, and activation of ERK1/2, p38 MAPK, and c-Src in mice. Furthermore, CYP1B1 could serve as a novel target for the development of agents that ameliorate hypertension and pathophysiological changes associated with hyperaldosteronism and salt.
Perspectives
The present study demonstrates a pivotal role of CYP1B1 in the cardiovascular and renal dysfunction, end-organ damage, and inflammation associated with DOCA-salt hypertension. Moreover, it reveals an important role of CYP1B1 in the regulation of catecholamine, AVP, and ET-1 levels that contribute to hypertension and associated pathophysiological changes produced by DOCA-salt treatment. The increased levels of these neurohumoral factors and the pathophysiological changes in DOCA-salt hypertension are most likely caused by activation of NADPH oxidase and ROS production by non-HETE AA metabolites via CYP1B1 and activation of ERK1/2, p38 MAPK, and c-Src. These observations, together with our previous work on Ang II-induced hypertension, [20] [21] [22] compel one to consider CYP1B1 as a potential therapeutic target. Selective inhibitors of this enzyme will be useful for the treatment of cardiovascular and renal dysfunction and end-organ damage associated with hypertension.
What Is New?
• Demonstration that cytochrome P450 (CYP) 1B1 is indispensable for cardiovascular and renal dysfunction, end-organ damage, and inflammation associated with deoxycorticosterone acetate-salt hypertension.
• CYP1B1 plays an important role in the regulation of catecholamines, arginine vasopressin, and endothelin-1 that are known to contribute to hypertension and associated pathophysiological changes produced by deoxycorticosterone acetate-salt.
• Nicotinamide adenine dinucleotide phosphate oxidase activity, generation of reactive oxygen species, and activation of extracellular signalregulated kinase 1/2, p38 mitogen-activated protein kinase, and cellular-Src in deoxycorticosterone acetate-salt hypertension are dependent on CYP1B1 activity.
What Is Relevant?
• This study advances our knowledge of the mechanism underlying pathogenesis of hypertension and demonstrates CYP1B1 as a potential therapeutic target for the development of agents to treat cardiovascular and renal dysfunction and end-organ damage associated with excess mineralocorticoid-salt hypertension. 
Materials
Dihydroethidium (DHE) was from Invitrogen™ (Carlsbad, CA). The cytochrome P450 (CYP) 1B1 antibody was purchased from BD Biosciences (Franklin Lakes, NJ). Antibodies against mouse Cyp1a1, cyclooxygenase (COX) 1, COX 2, 12/15 lipoxygenase, NOX-1, α-smooth muscle specific actin, CD-3, ERK1/2, p38 MAPK, and c-Src were purchased from Santa Cruz Biotechnology, Inc. (Santa Cruz, CA). Antibodies against rat CYP4A1/A2/A3 (recognizes mouse orthologs CYP4A10/A12/A14) and human CYP2B6 (recognizes mouse ortholog CYP2B10) were from Millipore (Billerica, MA), and the phospho ERK1/2, phospho p38 MAPK and phospho c-Src antibodies were purchased from Cell Signaling Technology, Inc. (Danvers, MA). The antibody against human CYP4F2 (most likely recognizes mouse orthologs CYP4F13/F15) was from Research Diagnostics, Inc. (Flanders, NJ), and the antibody against mouse F4/80 was from AbD Serotec (Raleigh, NC). All other chemicals were purchased from Sigma (St. Louis, MO).
Animals
All experiments were performed according to the protocols approved by our Institutional Animal Care and Use Committee in accordance with the National Institutes of Health Guide for the Care and Use of Laboratory Animals. Cyp1b1 -/-mice were generated in the laboratory of Dr. Frank Gonzalez at the National Cancer Institute, and validated as previously described (1), backcrossed 10 generations to a C57BL/6 background, and then brother:sister mated to generate a homozygous line. Male C57BL/6 (Cyp1b1 and Cyp1b1 -/-mice was routinely assessed in our laboratory by PCR, as previously described (2) . For PCR analysis, genomic DNA was obtained from tail snips using the Wizard ® SV Genomic DNA Purification System (Promega, Madison, WI), according to the manufacturer's instructions.
DOCA-salt-induced hypertension in Cyp1b1
+/+ and Cyp1b1 -/-mice Mice were anesthetized with ketamine (50 mg/kg, i.p.) and xylazine (50 mg/kg, i.p.), and all animals underwent unilateral left nephrectomy via flank incision. In one group of Cyp1b1 +/+ and one group of Cyp1b1 -/-mice, a silastic (Dow Corning ® , Midland, MI) pellet containing 50 mg/kg DOCA was subcutaneously implanted; these animals also received 1% NaCl in drinking water. Animals that underwent uninephrectomy only (sham) were given normal tap water for drinking. Systolic blood pressure was measured every 7 days for 28 days using a non-invasive tail cuff method (Kent Scientific, Torrington, CT; model XBP 1000). Prior to the start of the experiment, mice were acclimated to the blood pressure measuring device for 2 weeks.
Cyp1b1 activity assay
Cyp1b1 activity was determined using the P450-Glo™ Assay Kit (Promega) as described (3, 4) . At the end of the experiment, animals were anesthetized as described above, the left ventricle was punctured, and blood was flushed out by perfusion with cold saline (3 min). The heart and kidney were dissected free, cleaned of surrounding tissue, snap frozen in liquid N 2 , and stored at -80°C until use. Tissue samples were homogenized (2 x 3 min) in ice-cold 100 mmol/L potassium phosphate buffer (pH 7.4) using a TissueLyser II (QIAGEN, Valencia, CA). Following homogenization, samples were centrifuged at 10,000 g for 20 min at 4°C, and the supernatant was collected and stored at -80°C until further use. Protein content in the samples was determined by the Bradford method, and 500 µg of protein was added to a reaction mixture containing 20 µmol/L L-CEE substrate and 100 mmol/L potassium phosphate buffer (pH 7.4) and incubated at 37°C for 10 min. 100 µmol/L of NADPH (final concentration) was added, and the solution was further incubated at 37°C for 45 min. Finally, a 1:1 volume of luciferin detection reagent was added to the samples, and they were mixed for 10 sec after which they were incubated at room temperature for 20 min. Luminescence was measured using a luminometer (Turner Designs, Sunny Vale, CA; model TD-20/20). Potassium phosphate buffer was used as a blank and subtracted from each reading; activity was expressed as relative luminescence units (RLU).
Western blot analysis
Animals were anesthetized, and the heart and kidney removed as described above. Tissue samples were homogenized in lysis buffer, and protein content was determined by the Bradford method. Approximately 10 µg of protein was loaded and resolved on 8% SDS-polyacrylamide gels and processed for western blot analysis as described (5). Blots were probed with different primary and corresponding secondary antibodies, and intensity of the bands was measured with ImageJ 1.42 software (http://rsb.info.nih.gov/nih-image; National Institutes of Health). Protein expression of CYP isoforms, other AA metabolizing enzymes, and NOX1 were calculated as a ratio of expression of α-actin, and activities of signaling molecules (ERK1/2, p38 MAPK, and cSrc) were calculated as a ratio of phosphorylated protein to their corresponding nonphosphorylated levels.
Measurement of cardiac hypertrophy
Heart weight:body weight ratio: At the completion of the experiment and prior to sacrifice, animals were weighed. Immediately following sacrifice, hearts were removed and their wet weight determined. The ratio of heart weight (mg) to body weight (g) was calculated and used as a measure of cardiac hypertrophy.
Non-invasive measurement of cardiac function
Mice were anesthetized with 1% isoflurane via nose cone at a flow rate of 0.5 L/min. Electrocardiogram, respiration, and rectal temperatures were continuously monitored with an integrated physiology platform and temperature was maintained at 37°C with a heated platform and ceramic heating lamp. Cardiac function and structural changes were measured using the Vevo 2100 ultrasound machine (VisualSonics, Toronto, Canada). Measurement of the thickness of the interventricular septum, left ventricular (LV) posterior wall, LV anterior wall, as well as the end diastolic LV internal diameter, end systolic LV internal diameter, end diastolic volume (EDV), and end systolic volume (ESV) were determined using M-mode images in the parasternal long axis and the LV short-axis views at the mid-papillary level as described (6) . Stroke volume was calculated as EDV-ESV. Percent fractional shortening and ejection fraction were calculated as described (6) . The mitral annulus longitudinal velocities (E′ and A′) were determined by tissue Doppler from the apical 4-chamber view with the sample volume placed at the septal side of the mitral annulus (7).
Measurement of renal vascular function and structural changes
Vascular reactivity: Following anesthesia (described above), the renal artery was quickly dissected free, cleaned of surrounding tissue, and approximately 2 mm rings were mounted in a dual-wire myograph system (Danish Myo Technology, Aarhus, Denmark; model 610M). Vessels were continuously bathed in Krebs buffer (composition in mmol/L: 118 NaCl, 4.7 KCl, 25 NaHCO 3 , 1.2 MgSO 4 , 1.2 KH 2 PO 4 , 11.1 glucose, 2.5 CaCl 2 .2H 2 O) at 37°C, which was gassed with 95% O 2 and 5% CO 2 to maintain the pH at 7.4. An initial tension of 3 mN was placed on the vessels and allowed to equilibrate for approximately 30 min. To confirm the viability of the vessels, they were initially tested for constriction to 60 mmol/L KCl and then washed three times with fresh Krebs buffer. Cumulative concentration response curves to phenylephrine (PE) and endothelin-1 (ET-1) were obtained and responses measured as force of contraction in mN.
Endothelium-dependent and -independent vasodilation: Endothelial function was examined by constricting the renal artery with the concentration of PE that evoked a maximal response followed by addition of increasing concentrations of acetylcholine (ACh). Changes in the response of vessels to ACh were measured and presented as a percentage of the PE-induced constriction. Endothelium-independent vasodilation was studied by constricting the renal artery with the concentration of PE that evoked a maximal response followed by addition of increasing concentrations of sodium nitroprusside (SNP). Changes in the response of vessels to SNP were measured and presented as a percentage of the PE-induced constriction.
Measurement of media:lumen ratio: Following anesthesia (described above), the renal artery was dissected free, cleaned of surrounding tissue, placed in O.C.T. compound, and frozen at -80°C. 10 µm sections were cut using a cryostat (Leica Microsystems, Bannockburn, IL; model CM1850) and stained with standard hematoxylin and eosin. Sections were viewed with an Olympus 
Measurement of renal hemodynamics
Renal blood flow: Renal blood flow (RBF) was measured in mice using a 0.5-V Transonic renal flow probe attached to a TS420 perivascular flow meter (Transonic Systems, Ithaca, NY) as described (8) . Briefly, mice were anesthetized as described above and placed on a 37°C heated surgery table. The kidney was exposed from a subcostal flank incision, and the renal artery was isolated from the renal vein. After equilibrating for approximately 15 min, RBF was recorded for a 10 min period, and the average RBF over this time period was calculated and expressed in ml/min.
Renal vascular resistance: Renal vascular resistance was calculated as MAP/RBF.
Measurement of ROS production
To measure ROS production, vascular, cardiac, and renal sections were exposed to dihydroethidium (DHE), following the previously described and validated method (9) . Fresh, unfixed tissue samples were placed in O.C.T. compound and frozen at -80°C. Tissue segments were cut into 30 µm sections using a cryostat and placed on a glass slide. Sections were incubated in PBS for 30 min at 37°C, and then DHE, 2 µmol/L for vascular (9) and cardiac (10) sections, or 5 µmol/L for renal sections (11) , was topically applied. Cover slips were applied, and sections were further incubated at 37°C in a light-protected humidified chamber for 30 min. Sections were then rinsed in PBS, and fluorescence was detected using a 585-nm filter using an Olympus 
Analysis of renal hypertrophy and function
Kidney weight:body weight ratio: At the completion of the experiment and prior to sacrifice, animals were weighed. Immediately following sacrifice, the remaining kidney was removed and its wet weight determined. The ratio of kidney weight (mg) to body weight (g) was calculated and used as a measure of renal hypertrophy.
Proteinuria: For urine collection, individual mice were housed in metabolic cages for 24 h prior to the end of the experiment, allowing for the separation of urine from fecal material and food waste. Urine was collected in tubes that contained a small volume of mineral oil to prevent evaporation. Following calculation of volume, urine was aliquoted and stored at -80°C until further analysis. Urine was analyzed for protein content by the standard Bradford method.
Immunohistochemical analysis
At the completion of the experiment, animals were anesthetized as described above, the carotid artery was cannulated, and the animals were perfused with saline (3 min). The kidney was dissected free, placed in O.C.T compound, and frozen at -80°C. Sections (10 µm) were processed for α-smooth muscle actin (interstitial fibrosis), CD-3 (T cell infiltration), and F4/80 (macrophages) immunohistochemistry, Gomori trichrome staining (proteinaceous cast formation), and standard hematoxylin and eosin staining (tubular dilation) as described previously (12) . The stained cells were viewed and photographed as described above.
Determination of plasma levels of catecholamines, ET-1, and arginine vasopressin (AVP)
Plasma: At the completion of the experiment, animals were anesthetized as described above, and blood was withdrawn directly from the abdominal aorta and transferred to K + -EDTA tubes (BD Vacutainer ® ; BD Biosciences). Blood was centrifuged at 1,500 g for 15 min at 4°C, and the plasma was collected and stored at -80°C until further analysis.
Catecholamines (epinephrine and norepinephrine): Plasma levels of epinephrine and norepinephrine were kindly measured by Dr. Raymond Johnson of the CMN/KC neurochemistry core laboratory at Vanderbilt University using HPLC. Catecholamines were first extracted from plasma by mixing with dihydroxybenzylamine (internal standard), Tris buffer (pH 8.5) and 100 mg Al 2 O 3 . This solution was allowed to mix for 30 minutes, after which, the buffer was aspirated off, and the Al 2 O 3 was washed with distilled water. The wash was again thoroughly aspirated off and the catecholamines desorbed from the Al 2 O 3 using 200 l of 0.1 N acetic acid. 75 l of sample was injected into a biogenic amine HPLC chromatograph (Waters Corporation, Milford, MA) (13) .
ET-1: Plasma ET-1 concentration was determined using an ET-1 Quantikine ® ELISA kit (R&D Systems, Minneapolis, MN) according to the manufacturer's instructions.
AVP: Plasma AVP concentration was determined using an Arg 
Determination of tissue levels of HETEs and EETs
AA metabolites generated in the heart and kidney of sham-operated and DOCA-salttreated Cyp1b1
and Cyp1b1 -/-mice were measured in tissue homogenates, which were prepared using the previously described method (14) , with some modifications. Briefly, tissues were homogenized in acetonitrile after which 5 µl of appropriate internal standard was added. Samples were sonicated at 4°C for 10 min and placed at -20°C overnight. Samples were centrifuged; the supernatant was transferred to a new tube and then dried under nitrogen. Samples were resuspended in 250-500 µl of methanol and dried under nitrogen. Prior to analysis, samples were resuspended in 20 µl of methanol and then separated on C 18 reverse-phase columns using water and acetonitrile with 0.005% acetic acid as a mobile phase. Internal standards, 5-, 11-, 12-, 15-, and 20-HETEs and 11,12-and 14,15-EETs were used. Samples were ionized by electrospray with a fragmentor voltage of 120 V and detected in a negative mode as described (15) .
Measurement of NADPH oxidase activity
NADPH oxidase activity was determined in tissue homogenates by measuring lucigenin (N,N′-dimethyl-9,9′-biacridinium dinitrate)-enhanced chemiluminescence, as described previously (16), with some modifications. Following anesthesia (described above), the heart and kidney were isolated, cleaned of surrounding tissue, snap frozen in liquid N 2 , and stored at -80°C until use. Tissue samples were homogenized (2 x 3 min) in ice-cold lysis buffer containing protease inhibitors (20 mmol/l phosphate buffer, 1 mmol/l EGTA, 10 µg/ml aprotinin, 0.5 µg/ml leupeptin, 0.7 µg/ml pepstatin, 0.5 mmol/l phenylmethylsulphonylfluoride, and 150 mmol/l sucrose) using a TissueLyser II (QIAGEN). Following homogenization, samples were sonicated, centrifuged at 10,000 g for 20 min at 4°C, and the supernatant was collected and stored at -80°C until further use. Protein content in the samples was determined by the Bradford method, and equal amounts of protein were combined 1:1 with a reaction mixture containing 5 µmol/l lucigenin (final concentration) and 100 µmol/l NADPH (final concentration). Luminescence was measured every minute for 10 min using a luminometer. Lysis buffer was used as a blank and subtracted from each reading and activity expressed as arbitrary units.
Statistical analysis
Data were analyzed by one-way analysis of variance followed by Neuman-Keuls posthoc test or Student's t-test. The values of a minimum of three different experiments are expressed as the mean ± SEM. P values < 0.05 were considered statistically significant. and Cyp1b1
-/-mice were sham-operated or DOCA-salt-treated for 28 days as described in Methods. Heart weight: body weight ratio, an indicator of cardiac hypertrophy, was calculated as described in Methods. and Cyp1b1
-/-mice were sham-operated or DOCA-salt-treated for 28 days as described in Methods. The media: lumen ratio of the renal artery from animals in each of the different treatment groups was calculated as described in Methods. 
Cyp1b1
+/+
and Cyp1b1
-/-mice were sham-operated or DOCA-salt-treated for 28 days as described in Methods. Mean arterial pressure (MAP), renal blood flow (RBF), and renal vascular resistance (RVR) were measured and/or calculated as described in Methods. -/-mice were sham-operated or DOCA-salt-treated for 28 days as described in Methods. Kidney weight: body weight ratio (KW:BW), an indicator of renal hypertrophy, and proteinuria were measured and/or calculated as described in Methods. 
+/+ and Cyp1b1
-/-mice were sham-operated or DOCA-salt-treated for 28 days as described in Methods. Plasma was isolated and analyzed for concentrations of the molecules shown above as described in Methods. -/-mice were sham-operated or DOCA-salt-treated for 28 days as described in Methods. Heart and kidney tissue was prepared and analyzed for concentrations of the eicosanoids shown above as described in Methods (n = 4-6 for all experiments, and data are expressed as mean ± SEM). mice using approximately 10 µg of protein for loading as described in Methods. Cyp1b1 protein expression is normalized against α-actin, which was used as a loading control. * P < 0.05 sham vs. corresponding value from DOCA-salt-treated animal (n = 3-6 for all experiments and data are expressed as mean ± SEM). and Cyp1b1 -/-mice were sham-operated or DOCA-salt-treated for 28 days as described in Methods. Protein expression of various AA metabolizing enzymes were measured in heart (A) and kidney (B) homogenates by western blot as described in Methods using approximately 10 µg of protein for loading. α-actin was used as a loading control and intensity of the bands was measured using ImageJ as described in Methods (n = 3 for all experiments and data are expressed as mean ± SEM). and Cyp1b1 -/-mice were sham-operated or DOCA-salt-treated for 28 days as described in Methods. Superoxide production, as determined by fluorescence intensity of 2-hydroxyethidium (2-OHE), was measured in renal arteries as described in Methods. and Cyp1b1 -/-mice were sham-operated or DOCA-salt-treated for 28 days as described in Methods. Superoxide production, as determined by fluorescence intensity of 2-hydroxyethidium (2-OHE), was measured in the heart (A) and kidney (D) as described in Methods. NADPH oxidase activity was measured in cardiac (B) and renal (E) homogenates as described in Methods. Protein expression of NOX1 was measured in cardiac (C) and renal (F) homogenates by western blot as described in Methods using approximately 10 µg of protein for loading. α-actin was used as a loading control and intensity of the bands was measured using ImageJ as described in Methods. ) (C, F) , as determined by phosphorylation of these kinases, were measured in cardiac (A-C) and renal (D-F) homogenates by western blot as described in Methods using approximately 10 µg of protein for loading. Corresponding non-phospho antibodies were used as loading controls and intensity of the bands was measured using ImageJ as described in Methods. 
DOCA-salt-induced hypertension is associated with increased cardiac and renal
